Blood brain barrier permeability increases with age in individuals with 22q11.2 deletion syndrome

22q11.2 deletion syndrome (22q11.2DS) is characterised by high rates of psychotic disorders and immune abnormalities. Blood-brain barrier (BBB) permeability is known to be a risk factor for schizophrenia and immune aberrations. Objective: To evaluate the relationship between psychosis and BBB permeability in this population. Methods: We examined two biomarkers for BBB permeability, s100 beta and neuron-specific enolase (NSE), in 22q11.2DS individuals with/without psychosis. The first cohort of this Israeli-Belgium study was comprised of 20 22q11.2DS adults (30.58 +/- 9.42 years) afflicted with a psychotic disorder, another group of 69 non-psychotic 22q11.2DS adults (23.42 +/- 8.36 years), and 58 healthy controls (26.39 +/- 7.77 years). A second cohort was comprised of 18 non-psychotic 22q11.2DS Israeli children (5.83 +/- 1.55 years) and 14 healthy controls (5.34 +/- 1.43 years). NSE and s100 beta serum levels were detected in all participants. Results: Both factors were elevated in adults with 22q11.2DS compared to healthy controls, specifically in the non-psychotic sub-group. In contrast, there were no significant differences in their levels between the two groups of the paediatric cohort. Conclusions: Increased BBB permeability seems to be a trait of 22q11.2DS that evolves sometime in early adulthood. Our findings are in line with previous reports on non-syndromic schizophrenia, and suggest potential novel neural pathways to psychosis in 22q11.2DS.